Literature DB >> 18768388

Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.

Nicole A Horenstein1, Fedra M Leonik, Roger L Papke.   

Abstract

The activation of heteromeric and homomeric nicotinic acetylcholine receptors was studied in Xenopus laevis oocytes to identify key structures of putative agonist molecules associated with the selective activation of homomeric alpha7 receptors. We observed that selectivity between alpha7 and alpha4beta2 was more readily obtained than selectivity between alpha7 and alpha3beta4. Based on structural comparisons of previously characterized selective and nonselective agonists, we hypothesize at least three chemical motifs exist that, when present in molecules containing an appropriate cationic center, could be associated with the selective activation of alpha7 receptors. We identify the three distinct structural motifs based on prototypical drugs as the choline motif, the tropane motif, and the benzylidene motif. The choline motif involves the location of an oxygen-containing polar group such as a hydroxyl or carbonyl separated by two carbons from the charged nitrogen. The tropane motif provides alpha7-selectivity based on the addition of multiple small hydrophobic groups positioned away from the cationic center in specific orientations. We show that this motif can convert the nonselective agonists quinuclidine and ethyltrimethyl-ammonium to the alpha7-selective analogs methyl-quinuclidine and diethyldimethyl-ammonium, respectively. We have shown previously that the benzylidene group of 3-2,4, dimethoxy-benzylidene anabaseine (GTS-21) converts anabaseine into an alpha7-selective agonist. The benzylidene motif was also applied to quinuclidine to generate another distinct family of alpha7-selective agonists. Our results provide insight for the further development of nicotinic therapeutics and will be useful to direct future experiments with protein structure-based modeling and site-directed mutagenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768388      PMCID: PMC2999882          DOI: 10.1124/mol.108.048892

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  51 in total

1.  Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites.

Authors:  Nicolas Le Novère; Thomas Grutter; Jean-Pierre Changeux
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 2.  The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences.

Authors:  Nicolas Le Novère; Pierre-Jean Corringer; Jean-Pierre Changeux
Journal:  J Neurobiol       Date:  2002-12

3.  PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor.

Authors:  Lisa M Broad; Catherine Felthouse; Ruud Zwart; Gordon I McPhie; Kathy H Pearson; Peter J Craig; Louise Wallace; Richard J Broadmore; John R Boot; Martine Keenan; S Richard Baker; Emanuele Sher
Journal:  Eur J Pharmacol       Date:  2002-10-04       Impact factor: 4.432

4.  Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.

Authors:  Brad A Acker; E Jon Jacobsen; Bruce N Rogers; Donn G Wishka; Steven C Reitz; David W Piotrowski; Jason K Myers; Mark L Wolfe; Vincent E Groppi; Bruce A Thornburgh; Paula M Tinholt; Rodney R Walters; Barbara A Olson; Laura Fitzgerald; Brian A Staton; Thomas J Raub; Michael Krause; Kai S Li; William E Hoffmann; Mihaly Hajos; Raymond S Hurst; Daniel P Walker
Journal:  Bioorg Med Chem Lett       Date:  2008-05-01       Impact factor: 2.823

5.  The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.

Authors:  Frank G Boess; Jean De Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Bernd Riedl; Katrin Schnizler; Franz-Josef van der Staay; Marja van Kampen; Welf Burkhard Wiese; Gerhard Koenig
Journal:  J Pharmacol Exp Ther       Date:  2007-02-16       Impact factor: 4.030

6.  alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues.

Authors:  C A Briggs; M R Schrimpf; D J Anderson; E J Gubbins; J H Grønlien; M Håkerud; H Ween; K Thorin-Hagene; J Malysz; J Li; W H Bunnelle; M Gopalakrishnan; M D Meyer
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

7.  The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase.

Authors:  Mario B Marrero; Roger L Papke; Balwinder S Bhatti; Seán Shaw; Merouane Bencherif
Journal:  J Pharmacol Exp Ther       Date:  2004-01-13       Impact factor: 4.030

8.  Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.

Authors:  William R Kem; Vladimir M Mahnir; Laszlo Prokai; Roger L Papke; Xuefang Cao; Susan LeFrancois; Kristin Wildeboer; Katalin Prokai-Tatrai; Julia Porter-Papke; Ferenc Soti
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

9.  3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner.

Authors:  E M Meyer; E T Tay; R L Papke; C Meyers; G L Huang; C M de Fiebre
Journal:  Brain Res       Date:  1997-09-12       Impact factor: 3.252

10.  Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.

Authors:  Roger L Papke; Julia K Porter Papke
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

View more
  32 in total

1.  Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.

Authors:  Nicole A Horenstein; Roger L Papke; Abhijit R Kulkarni; Ganesh U Chaturbhuj; Clare Stokes; Khan Manther; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2016-01-07       Impact factor: 5.157

2.  Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.

Authors:  Roger L Papke; Caryn Trocmé-Thibierge; Daniela Guendisch; Shehd Abdullah Abbas Al Rubaiy; Stephen A Bloom
Journal:  J Pharmacol Exp Ther       Date:  2011-02-01       Impact factor: 4.030

Review 3.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

4.  Macroscopic and Microscopic Activation of α7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107.

Authors:  Marta Quadri; Sumanta Garai; Ganesh A Thakur; Clare Stokes; Alican Gulsevin; Nicole A Horenstein; Roger L Papke
Journal:  Mol Pharmacol       Date:  2018-10-22       Impact factor: 4.436

5.  Intrinsically low open probability of α7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures.

Authors:  Dustin K Williams; Can Peng; Matthew R Kimbrell; Roger L Papke
Journal:  Mol Pharmacol       Date:  2012-07-24       Impact factor: 4.436

6.  Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.

Authors:  Asti Jackson; Roger L Papke; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

7.  The minimal pharmacophore for silent agonism of the α7 nicotinic acetylcholine receptor.

Authors:  Roger L Papke; Kinga Chojnacka; Nicole A Horenstein
Journal:  J Pharmacol Exp Ther       Date:  2014-07-02       Impact factor: 4.030

8.  Point-to-point ligand-receptor interactions across the subunit interface modulate the induction and stabilization of conformational states of alpha7 nAChR by benzylidene anabaseines.

Authors:  Matthew D Isaacson; Nicole A Horenstein; Clare Stokes; William R Kem; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2013-01-23       Impact factor: 5.858

9.  An Unaltered Orthosteric Site and a Network of Long-Range Allosteric Interactions for PNU-120596 in α7 Nicotinic Acetylcholine Receptors.

Authors:  Christopher B Marotta; Henry A Lester; Dennis A Dougherty
Journal:  Chem Biol       Date:  2015-07-23

10.  An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline.

Authors:  Ethan B Van Arnam; Emily E Blythe; Henry A Lester; Dennis A Dougherty
Journal:  Mol Pharmacol       Date:  2013-05-16       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.